Nilanjan Ghosh, MD, PhD, on Paving the Way for CAR T Therapies in Lymphomas

Video

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.

“Some work that needs to be done would be development of products which have lower manufacturing time, another would be a more rapid process for financial clearance for commercial parties. We need to understand that the disease is aggressive in many cases, and we just can't wait 4 weeks to get clearance. Another thing would be building relationships with physicians and educating them about indications for CAR T.”

The last few years have seen chimeric antigen receptor (CAR) T-cell therapy approvals in hematologic malignancies including lisocabtagenemaraleucel (Breyanzi), axicabtagenecliolecleucel (Yescarta), brexucabtageneautoleucel (Tecartus) and ciltacabtageneautoleucel (Carvykti). With these approvals, clinicians are beginning to see the long-term impact of these treatments in the clinic

Nilanjan Ghosh, MD, PhD, chief of the lymphoma division and oncologist at Levine Cancer Institute, is one such clinician with first-hand experience with cell therapies in lymphoma. CGTLive spoke to Ghosh to learn more about work that needs to be done to support the growing prominence of CAR T-cell therapies in cancer treatment and future therapies to come to market. He also noted some questions that remain to be researched with these cell therapies.

Related Videos
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Abhishek Gupta, BS, the senior vice president of genetic medicines at Syneos Health
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Luke Roberts, MBBS, PhD, on Early Clinical Data on Congestive Heart Failure Gene Therapy
Lawrence R. Lustig, MD, the chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians
© 2024 MJH Life Sciences

All rights reserved.